Pharmacokinetic analysis of gefitinib in a patient with advanced non‐small cell lung cancer undergoing hemodialysis

Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non‐small cell lung cancer and...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jinmei, Ni, Li, Wang, Mengzhao, Zhong, Wei, Xiao, Yi, Zheng, Ke, Hu, Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773293/
https://www.ncbi.nlm.nih.gov/pubmed/27042230
http://dx.doi.org/10.1111/1759-7714.12263
Descripción
Sumario:Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non‐small cell lung cancer and treated with orally administered gefitinib. We analyzed the pharmacokinetic data of gefitinib in this patient and found that that gefitinib was safe under these conditions.

Ejemplares similares